| Literature DB >> 29281726 |
Valerie Hongoh1,2, Pierre Gosselin3,4, Pascal Michel1,5, André Ravel1,2, Jean-Philippe Waaub6, Céline Campagna3,7, Karim Samoura8.
Abstract
Prioritizing resources for optimal responses to an ever growing list of existing and emerging infectious diseases represents an important challenge to public health. In the context of climate change, there is increasing anticipated variability in the occurrence of infectious diseases, notably climate-sensitive vector-borne diseases. An essential step in prioritizing efforts is to identify what considerations and concerns to take into account to guide decisions and thus set disease priorities. This study was designed to perform a comprehensive review of criteria for vector-borne disease prioritization, assess their applicability in a context of climate change with a diverse cross-section of stakeholders in order to produce a baseline list of considerations to use in this decision-making context. Differences in stakeholder choices were examined with regards to prioritization of these criteria for research, surveillance and disease prevention and control objectives. A preliminary list of criteria was identified following a review of the literature. Discussions with stakeholders were held to consolidate and validate this list of criteria and examine their effects on disease prioritization. After this validation phase, a total of 21 criteria were retained. A pilot vector-borne disease prioritization exercise was conducted using PROMETHEE to examine the effects of the retained criteria on prioritization in different intervention domains. Overall, concerns expressed by stakeholders for prioritization were well aligned with categories of criteria identified in previous prioritization studies. Weighting by category was consistent between stakeholders overall, though some significant differences were found between public health and non-public health stakeholders. From this exercise, a general model for climate-sensitive vector-borne disease prioritization has been developed that can be used as a starting point for further public health prioritization exercises relating to research, surveillance, and prevention and control interventions in a context of climate change. Multi-stakeholder engagement in prioritization can help broaden the range of criteria taken into account, offer opportunities for early identification of potential challenges and may facilitate acceptability of any resulting decisions.Entities:
Mesh:
Year: 2017 PMID: 29281726 PMCID: PMC5744945 DOI: 10.1371/journal.pone.0190049
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow chart of steps conducted to create disease prioritization models.
Article selection process for review.
| Steps | Total articles | |
|---|---|---|
| 1 | Initial keyword search in Pubmed of studies containing combinations of the following keywords: “emerging”, “infectious”, “communicable”, “zoonotic”, “disease” and “prioritization”. | N = 1196 |
| 2 | Title and abstract scan of articles from Step 1 scanned for relevance resulting in 37 studies describing describing disease prioritization studies. | N = 37 |
| 3 | Related peer reviewed and grey literature articles referenced by articles retained in step 2 were also scanned for relevance (snowball search). | N = 42 |
| 4 | Final article selection of studies in which prioritization criteria were explicitly listed or described | N = 26 |
*Note: In some cases, multiple articles referred to different aspects of the same study
Summary of reviewed disease prioritization studies.
| Author & year | Country | Objective | Criteria | Weights | # | Item type | Method overview | |
|---|---|---|---|---|---|---|---|---|
| Carter 1991 | Canada | Set priorities for national surveillance (notifiable list) | B | 12 | No | 60 | Communicable diseases | Committee (n = 6) scored and discussed. Un-weighted criteria. Cut-off set for inclusion of diseases on notifiable list. |
| Rushdy et al 1998 | UK | Rank diseases to manage resources | C | 6 | No | 41 | 33 communicable diseases and 8 generic diseases | Expert opinion, questionnaire—assessed by experts in communicable diseases (n = 194) |
| Doherty 2000 | Canada | To inform resource allocation national level | B, D | 10 | No | 43 | Communicable diseases | Expert opinion and consensus of subcommittee (n = 6) |
| Horby et al 2001 | UK | Rank diseases to manage resources | B, C | 5 | No | 69 | 58 pathogens and 11 generic diseases | Expert opinion (n = 518) |
| Valenciano 2002 (InVS) | France | Determine priorities to improve knowledge, prevention and control of diseases | A, B, C | 6 | No | 37 | Non-food borne zoonoses | Expert opinion (n = 10) |
| WHO 2002 (Dubrovnik pledge) | WHO—7 eastern European countries | Strengthen infectious disease surveillance systems in 7 countries of South-East Europe | B | 8 | No | 53 | Communicable diseases | Expert opinion (n = 24) |
| Doherty | Canada | Strengthen national surveillance capacities | B | 10 | No | 48 | Communicable diseases | Expert opinion and consensus of subcommittee (n = 6) |
| McKenzie et al 2007 | New Zealand | Prioritize wildlife pathogens for surveillance | B | 3 | No | 82 | Wildlife pathogens | OIE based risk assessment approach |
| Krause et al 2008a&b | Germany | Guide research and surveillance strategies of department | A,B | 12 | Yes | 85 | Pathogens | Expert opinion (n = 11) and weighted sum aggregation |
| Cardoen et al 2009 | Belgium | Rank food and water-borne pathogens to prioritize resource allocation for management | C | 5 | Yes | 51 | Food and water-borne zoonotic pathogens | Expert opinion (n = 35) and weighted sum aggregation |
| Capek 2010 (InVS) | France | Rank non-foodborne zoonoses and anticipate emerging threats linked to climate, etc. | A, B, C | 6 | No | 37 | Non-food borne zoonoses | Expert opinion (n = 16) |
| Havelaar et al 2010 | The Netherlands | Prioritized emerging zoonoses to support an early warning and surveillance network | B | 7 | Yes | 86 | Emerging zoonotic pathogens | MCDA technique. Existing list and expert opinion determined list of pathogens, weighting of criteria based on panel consultation (n = 29) |
| Pavlin et al 2010 | Pacific Island nations | Update list of pathogens to include on urgent NNDL list | B, D | 12 | Yes | 27 | Conditions/diseases assessed | Additive model—Sum of scores |
| Ruzante et al 2010 | Canada | Framework to prioritize foodborne risks | D | 4 | Yes | 6 | Pathogen-food combinations | MCDA technique—PROMETHEE |
| Balabanova et al 2011 | Germany | Rank infectious diseases for research and surveillance | B | 10 | Yes | 127 | Pathogens | Expert opinion (n = 83) and weighted sum aggregation |
| Humblet et al 2012 | Europe | European collaboration and agreement on priority zoonoses for surveillance and eradication | B, C | 57 | Yes | 100 | Zoonoses | MCDA technique with Expert scoring (n = 40) with weighted sum aggregation and Monte Carlo simulation |
| Ng & Sargeant 2012a,b, 2013 | Canada | Compare zoonoses priorities between Canada and the US from public and expert perspective | A | 21 (59) | Yes | 62 | Zoonotic diseases | Criteria elicitation—via conjoint analysis technique conducted with public (n = 1500) and expert (n = 1471) focus groups and surveys, summed using part-worth utility values approach |
| Cediel et al 2013 | Colombia | Prioritize zoonoses for surveillance | B | 12 | Yes | 32 | Zoonoses | Delphi (n = 12) and additive model |
| Del Rio Vilas et al 2013 | UK | To inform management of emerging animal health related threats in UK | C | 10 | Yes | 111 | 111 threats, 74 unique | MCDA technique—Developed threat assessment tool |
| Cox et al 2013 | Canada | Test standardised method to prioritise infectious diseases of humans and animals that may emerge in response to CC | A | 40 | Yes | 9 | Trialed on 9 test pathogens | MCDA technique—MACBETH and additive model (n = 64) |
| Kadohira et al 2015 | Japan | Surveillance and management of zoonoses | B, C | 7 | Yes | 98 | Zoonoses | Author determined criteria, risk profiles generated and reviewed by experts (n = 76) with AHP attributed weights by stakeholder groups (n = 334) |
| Brookes et al 2014 a&b | Australia | Prioritize exotic pig diseases for management | C | 9 | Yes | 30 | Diseases | MCDA technique with stakeholder (n = 81) elicited weight preference via online survey |
^ Country targeted by prioritization exercise
* Not peer reviewed
** A = research; B = surveillance; C = prevention & control; D = policy
†59 identified, but only 21 used in prioritization exercises
‡3 models (perception (3 criteria), impacts (4 criteria) and capabilities (3 criteria))
Stakeholder validated list of criteria for the prioritization of climate sensitive vector-borne diseases.
| Category | Criteria | Effect direction | Measurement units |
|---|---|---|---|
| Public Health | PHC-01 –Reported yearly incidence of human cases in country | Maximize | 0: Nil; 1: Very Low (<5); 2: Low (6–30); 3: Moderate (31-; 100): High (101–500); 5: very high (>500); 6: Unknown |
| PHC-02 –Severity of the disease (both physically and mentally) | Maximize | 0: Nil; 1: Low severity; 2: Moderate severity; 3: High severity; 4: Very high severity (risk of mortality) | |
| PHC-03 –Vulnerable groups | Maximize | 0: All are vulnerable; 1: Existence of higher risk groups (e.g. 0-5yrs) | |
| PHC-04 –Potential to increase social inequality | Maximize | 0: No effect on social inequality; 1: Likely to exacerbate social inequality | |
| Social Impact | SIC-01 –Risk perception of the public | Maximize | 1: Low perceived importance; 2: Moderate importance; 3: High importance |
| SIC-02 –General level of knowledge, attitude and behaviour of the public | Minimize | 1: Little or no knowledge; 2: Moderate knowledge (general idea of symptoms); 3: High knowledge (can recognize symptoms and aware of transmission and treatment) | |
| Risk and Epidemiology | REC-01 –Existence of favourable conditions for disease transmission | Maximize | 1: Low risk (climate not suitable, no vector and no reservoir hosts); 2: Moderate risk (one of components present, either suitable climate, vector or reservoir host); 3: High risk (all components present–suitable climate, vector and reservoir host—or current or historic transmission) |
| REC-02 –Epidemic potential | Maximize | 1: Low risk; 2: high risk | |
| REC-03 –Current global trend of disease over last 5 years | Maximize | 1: Stable–little to no recent local or global change in transmission; 2: unstable–recent global changes in transmission; 3: very unstable–recent local changes in transmission | |
| REC-04 –Proportion of susceptible population | Maximize | 1: very low 0–5%; 2: low 5–10%; 3: moderate 10–25%; 4: high 25–50%; 5: very high 50+ | |
| Animal and Environmental Health Criteria (AEC) | AEC-01 –Estimated prevalence of yearly animal cases | Maximize | 0: not transmissible to animals; 1: very low (<5%); 2: low (5–10%); 3: moderate (10–25%); 4: high (25–50%); 5: very high (50+); 6: unknown prevalence |
| AEC-02 –Severity of disease | Maximize | 0: Not applicable; 1: Low severity; 2: Moderate severity; 3: High severity; 4: Very high severity (risk of mortality) | |
| AEC-03 –Environmental or animal reservoir stage | Maximize | 1: Low risk–no independent stages that can survive in environment, water or reservoir hosts; 2: higher risk–existence of independent stages that can survive in environment, water or reservoir hosts. | |
| Economic Criteria (ECC) | ECC-01 –Cost to provincial government | Maximize | 1: low costs; (a few thousand); 2: moderate costs (hundreds of thousands); 3: high costs (millions) |
| ECC-02 –Cost to private sector | Maximize | 1: low costs (<100$); 2: moderate costs (<1000$); 3: high costs (>1000$) | |
| ECC-03 –Cost to individuals | Maximize | 1: low costs (<100$); 2: moderate costs (<1000$); 3: high costs (>1000$) | |
| Strategic and Operational Criteria (SOC) | SOC-01 –Capacity to detect and diagnose | Minimize | 0: no tests, symptoms difficult to recognize; 1: distinct symptoms or existence of tests |
| SOC-02 –Existence and effectiveness of current treatments | Minimize | 0: no existing treatment; 1: partially effective treatment; 2: highly effective treatment available | |
| SOC-03 –Level of scientific knowledge of the disease | Minimize | 1: low–very little knowledge; 2: moderate–partial yet incomplete knowledge of disease symptoms, transmission, risk factors and treatment; 3: high–symptoms, transmission, risk factors and treatment well known | |
| SOC-04 –Optimization opportunities | Maximize | 0: no opportunities; 1: potential opportunities | |
| SOC-05– Reportable disease | Maximize | 0: not reportable; 1: nationally or internationally reportable |
* Criteria added by stakeholders
Fig 2Criteria category weight average comparison by intervention domain.
The span of stakeholder weights is indicated by the vertical lines with shaped makers indicating the intervention specific group means. Criteria categories are shown along the X axis with average weights by category shown along the Y axis. The differences between the weights given to each intervention domain (research, surveillance and prevention & control) were not found to be significantly different for any of the categories. Criteria category Legend (X axis): PHC: Public Health Criteria; SIC: Social Impact Criteria; REC: Risk and Epidemiology Criteria; AEC: Animal and Environmental Health Criteria; ECC: Economic Criteria; SOC: Strategic and Operational Criteria.
Fig 3Individual weights by criteria and intervention domain.
Each line in the graph represents each of the 10 Individual stakeholder’s (S1-S10) weight assignments on all 21 criteria. The relative importance of criteria within each category is seen to vary depending on the intervention domain. For example: the “SOC-03-level of knowledge” criterion received the most weight in the research domain, while the “SOC-01-capacity to detect disease” criterion received the most weight in the surveillance domain. The “SOC-02-Existence of treatment” received the most weight in the prevention and control domain.
Fig 4GAIA decision map for all intervention domains.
Panel A) shows the GAIA map for the research domain, B) shows the surveillance domain and C) the prevention and control domain. In each map, the bold red line represents the group decision axis (i.e. consensus ranking) with the filled circle pointing in the direction of the group ranking. Square markers represent the ranking of the different diseases in k-dimensional space (where k represents the number of criteria) projected onto a 2-dimensional plane. Diseases closest to the group decision axis are prioritized over diseases further away from the decision axis. Stakeholders 1 through 10 are represented by the blue circular markers labelled S1-S10. Stakeholders pointing in the same direction as the group decision axis are most aligned with the group ranking. Stakeholders further away in space from each other and from the group decision axis have more disparate weighting tendencies and hence perspectives. For example, in panel A) S8 shows distinct weight position as compared with the rest of the stakeholders and therefore indicates a different set of values in this context as compared with the rest of the group. Clusters of stakeholders can also be observed occurring in each of the panels and indicate stakeholders with more similar weightings (i.e. perspectives). For example, in panel B) weights by stakeholders S2 and S6 are more similar to each other than to stakeholders S1 and S8.
Pilot prioritization of diseases for the group and by stakeholder for each intervention domain.
| GRP | S1 | S2 | S3 | S4 | S5 | S6 | S7 | S8 | S9 | S10 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diseases | Rnk | Phi | Rnk | Phi | Rnk | Phi | Rnk | Phi | Rnk | Phi | Rnk | Phi | Rnk | Phi | Rnk | Phi | Rnk | Phi | Rnk | Phi | Rnk | Phi |
| West Nile virus (WNV) | 1 | 0.08 | 2 | 0.09 | 3 | -0.01 | 3 | 0.02 | 3 | -0.00 | 1 | 0.10 | 2 | 0.17 | 1 | 0.10 | 1 | 0.09 | 4 | -0.01 | 2 | 0.31 |
| Lyme (LYM) | 2 | 0.07 | 1 | 0.13 | 1 | 0.14 | 2 | 0.04 | 4 | -0.03 | 3 | -0.01 | 1 | 0.18 | 2 | 0.03 | 4 | -0.06 | 3 | 0.00 | 1 | 0.23 |
| Dengue (DEN) | 3 | -0.01 | 3 | -0.02 | 4 | -0.04 | 4 | -0.03 | 2 | 0.04 | 4 | -0.03 | 3 | -0.07 | 4 | 0.01 | 2 | 0.08 | 2 | 0.01 | 4 | -0.15 |
| Malaria (MAL) | 4 | -0.02 | 4 | -0.12 | 2 | 0.05 | 1 | 0.05 | 1 | 0.05 | 2 | 0.00 | 4 | -0.08 | 3 | 0.02 | 5 | -0.18 | 1 | 0.02 | 3 | -0.05 |
| Chikungunya (CHIKV) | 5 | -0.11 | 5 | -0.13 | 5 | -0.13 | 5 | -0.08 | 5 | -0.06 | 5 | -0.06 | 5 | -0.20 | 5 | -0.16 | 3 | 0.07 | 5 | -0.03 | 5 | -0.35 |
| West Nile virus (WNV) | 2 | 0.10 | 2 | 0.02 | 1 | 0.15 | 3 | 0.02 | 4 | 0.00 | 1 | 0.15 | 2 | 0.10 | 2 | 0.15 | 2 | 0.26 | 1 | 0.04 | 2 | 0.16 |
| Lyme (LYM) | 1 | 0.14 | 1 | 0.18 | 2 | 0.10 | 2 | 0.04 | 3 | 0.03 | 2 | 0.08 | 1 | 0.13 | 1 | 0.13 | 1 | 0.38 | 2 | 0.03 | 1 | 0.27 |
| Dengue (DEN) | 3 | -0.02 | 3 | 0.00 | 3 | -0.01 | 4 | -0.03 | 1 | 0.08 | 3 | -0.01 | 3 | -0.02 | 3 | -0.00 | 3 | -0.13 | 3 | -0.01 | 4 | -0.07 |
| Malaria (MAL) | 4 | -0.06 | 5 | -0.12 | 4 | -0.07 | 1 | 0.05 | 2 | 0.06 | 4 | -0.09 | 4 | -0.06 | 4 | -0.05 | 5 | -0.27 | 4 | -0.01 | 3 | -0.03 |
| Chikungunya (CHIKV) | 5 | -0.16 | 4 | -0.08 | 5 | -0.18 | 5 | -0.08 | 5 | -0.18 | 5 | -0.13 | 5 | -0.15 | 5 | -0.22 | 4 | -0.25 | 5 | -0.04 | 5 | -0.33 |
| West Nile virus (WNV) | 1 | 0.10 | 1 | 0.14 | 1 | 0.21 | 3 | 0.02 | 1 | 0.12 | 1 | 0.10 | 2 | 0.05 | 1 | 0.10 | 2 | 0.05 | 1 | 0.05 | 2 | 0.15 |
| Lyme (LYM) | 2 | 0.06 | 2 | 0.11 | 2 | 0.15 | 2 | 0.04 | 3 | -0.02 | 2 | 0.07 | 1 | 0.09 | 2 | 0.03 | 4 | -0.03 | 2 | 0.04 | 1 | 0.14 |
| Dengue (DEN) | 4 | -0.02 | 3 | -0.03 | 4 | -0.09 | 4 | -0.03 | 2 | 0.02 | 4 | -0.02 | 3 | -0.00 | 3 | 0.02 | 1 | 0.06 | 4 | -0.02 | 4 | -0.07 |
| Malaria (MAL) | 3 | -0.01 | 5 | -0.12 | 3 | -0.08 | 1 | 0.05 | 4 | -0.03 | 3 | 0.02 | 4 | -0.01 | 4 | -0.01 | 3 | -0.02 | 3 | 0.01 | 3 | 0.06 |
| Chikungunya (CHIKV) | 5 | -0.13 | 4 | -0.10 | 5 | -0.19 | 5 | -0.08 | 5 | -0.09 | 5 | -0.16 | 5 | -0.13 | 5 | -0.14 | 5 | -0.07 | 5 | -0.07 | 5 | -0.28 |
GRP–overall group ranking; Rnk–rank; S1-S10 –denotes stakeholders 1 through 10; Phi–net outranking flows (combined positive and negative flows) indicating performance of each disease
Disease evaluation matrix.
| Diseases | Criteria | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PHC1 | PHC2 | PHC3 | PHC4 | SIC1 | SIC2 | REC1 | REC2 | REC3 | REC4 | AEC1 | AEC2 | AEC3 | ECC1 | ECC2 | ECC3 | SOC1 | SOC2 | SOC3 | SOC4 | SOC5 | |
| West Nile virus (WNv) | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 1 | 5 | 6 | 4 | 2 | 1 | 1 | 1 | 1 | 0 | 3 | 1 | 1 |
| Lyme (LYM) | 3 | 2 | 1 | 1 | 1 | 2 | 3 | 1 | 3 | 5 | 6 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 3 | 1 | 1 |
| Dengue (DENV) | 0 | 4 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 0 | 1 | 2 | 3 | 2 | 1 | 0 | 1 | 3 | 1 | 1 |
| Malaria (MAL) | 0 | 4 | 1 | 2 | 2 | 1 | 2 | 1 | 1 | 2 | 0 | 0 | 2 | 3 | 3 | 1 | 1 | 2 | 3 | 1 | 1 |
| Chikungunya (CHIKV) | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 0 | 1 | 2 | 1 | 1 | 2 | 1 | 0 | 2 | 1 | 1 |
Disease evaluation matrix showing evaluation scores for each of the five pilot diseases based on context specific data reviewed pertaining to each disease over all criteria. Note: Criteria AEC3, SOC4 and SOC5 are non-discriminating with the above data set due to lack of variation between disease evaluation values but could be discriminating with different diseases or more refined data set. Criteria were retained in the model due to expressed interest of stakeholders. PHC–Public health criteria; SIC–Social impact criteria; REC–Risk and epidemiology criteria; AEC–Animal and environmental health criteria; ECC–Economic criteria; SOC–Strategic and operational criteria
Weight stability intervals in descending order from sensitivity analysis of all stakeholders for the research domain.
| Criteria | S1 | S2 | S3 | S4 | S5 | S6 | S7 | S8 | S9 | S10 |
|---|---|---|---|---|---|---|---|---|---|---|
| REC-03 | 9 (0–10) | 6(2–100) | 10 (0–11) | 5 (0–5.5) | 2 (0–8) | 4 (0–10) | 5 (2–6) | 3 (0–4) | 5 (0–6) | 3 (0–6) |
| ECC-03 | 1 (0–2.5) | 5 (0–100) | 4 (0–6) | 5 (0–11) | 1 (0–9) | 3 (0–11) | 2 (0–100) | 2 (0–4) | 6 (0–8) | 3 (0–8) |
| SOC-02 | 4 (3–100) | 1 (0–10) | 6 (0–7) | 4 (0–5) | 10 (4–100) | 8 (2.5–100) | 9 (6–11) | 16 (15–100) | 4 (0–5) | 1 (0–100) |
| REC-01 | 9 (0–100) | 4 (0–100) | 3 (0–4.5) | 5 (4–10) | 10 (1.5–100) | 5 (0–100) | 6 (4.5–11) | 3 (2.5–100) | 5 (3.5–8) | 9 (0–100) |
| AEC-02 | 4 (1.5–100) | 3(0–20) | 3 (0–3) | 5 (0–5.5) | 5 (0–100) | 4 (0–100) | 2 (0–4) | 4 (3–100) | 4 (0–5) | 4 (0–100) |
| ECC-02 | 2 (0–14) | 5(0–9) | 2 (0.5–100) | 2 (1–100) | 4 (0–10) | 4 (0–9) | 2 (0–100) | 3 (0–4) | 4 (2.5–100) | 4 (0–23) |
| SOC-01 | 10 (0–20) | 1 (0–12) | 1 (0–8) | 5 (0–5.5) | 5 (0–14) | 6 (0–13) | 6 (0–7) | 16 (0–17) | 4 (0–5) | 1 (0–27) |
| PHC-01 | 6 (0–100) | 9 (4–100) | 5 (0–6) | 3 (0–6) | 2 (0–100) | 9 (1–100) | 11 (0–100) | 3 (2–100) | 3 (0–5) | 28 (0–100) |
| ECC-01 | 2 (0–3) | 5(0–13) | 4 (2–100) | 3 (0–100) | 5 (0–11) | 4 (0–9) | 2 (0–100) | 3 (0–3.5) | 4 (2.5–100) | 7 (0–15) |
| SIC-02 | 1 (0–12) | 3 (0–7) | 6 (4.5–100) | 4 (0.5–100) | 5 (0–12) | 4 (0–11) | 5 (0–16) | 3 (0–4) | 5 (3–100) | 3 (0–25) |
| REC-04 | 3 (0–13) | 4 (0–9) | 3 (1–100) | 10 (6–100) | 5 (0–12) | 4 (0–11) | 5 (0–100) | 3 (0–4) | 6 (4–100) | 4 (0–60) |
| AEC-01 | 3 (0–100) | 3(0–100) | 3 (0–4) | 0 (0–100) | 5 (0–100) | 3 (0–100) | 2 (0–100) | 4 (3–100) | 3 (0–5) | 4 (0–100) |
| PHC-02 | 6 (0–18) | 12 (0–17) | 10 (8.5–100) | 15 (11–100) | 5 (0–14) | 10 (0–18) | 12 (3.5–16) | 3 (0–4) | 4 (1.5–100) | 6 (0–31) |
| SIC-01 | 3 (0–19) | 3 (0–7) | 9 (7–100) | 1 (0.5–100) | 5 (0–12) | 6 (0–13) | 5 (3–16) | 3 (0–20.5) | 4 (3–100) | 2 (0–24) |
| REC-02 | 9 (8–100) | 6 (0–13) | 10 (0–11) | 10 (0–13) | 3 (0–100) | 7 (0–100) | 9 (0–12) | 3 (2.5–100) | 5 (0–7) | 10 (5–100) |
| SOC-03 | 10 (0–25) | 15 (0–29) | 4 (0–13) | 10 (0–17) | 10 (0–20) | 4 (0–21) | 5 (1–13.5) | 10 (0–12) | 5 (0–9) | 3 (0–36) |
| PHC-03 | 6 (0–100) | 9 (0–100) | 5 (0–100) | 5 (4–100) | 5 (0–100) | 6 (0–100) | 5 (3–100) | 3 (2–100) | 5 (4–100) | 4 (0–100) |
| PHC-04 | 2 (1–100) | 0 (0–100) | 5 (3–100) | 2 (0–100) | 3 (0–100) | 4 (0–100) | 3 (0–100) | 3 (0–100) | 6 (3.5–100) | 2 (0–100) |
| AEC-03 | 3 (0–100) | 3(0–100) | 5 (0–100) | 5 (4.5–100) | 5 (0–100) | 4 (0–100) | 2 (0–100) | 4 (0–100) | 6 (0–100) | 3 (0–100) |
| SOC-04 | 3 (0–100) | 3 (0–100) | 1 (0–100) | 1 (0–100) | 3 (0–100) | 4 (0–100) | 1 (0–100) | 3 (0–100) | 6 (0–100) | 0 (0–100) |
| SOC-05 | 1 (0–100) | 0 (0–100) | 1 (0–100) | 0 (0–100) | 2 (0–100) | 1 (0–100) | 1 (0–100) | 5 (0–100) | 6 (0–100) | 1 (0–100) |
S1-S10 –denotes stakeholders 1 through 10; Stakeholder assigned weights are given for all criteria followed by the stability interval in parentheses over which the ranking order for the 1st position items are maintained. PHC–Public Health criteria; SIC–Social impact criteria; REC–Risk and epidemiology criteria; AEC–Animal and environmental health criteria; ECC—Economic criteria; SOC–Strategic and operational criteria